JurongHealth Campus. Source: NTFGH
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Austco Healthcare (AHC) has been awarded a $1.3 million contract to update the nurse call system for the JurongHealth Campus in Singapore
  • The Tacera solution will be integrated with JurongHealth’s Code Blue Platform and will be the fastest code blue rapid response of any Singapore hospital
  • Tacera’s software is the only nurse call solution on the market that has voice over internet protocol (VoIP)
  • On market close, Austco is up 14.1 per cent and is trading at 10.5 cents per share

Austco Healthcare (AHC) has won a $1.3 million contract to update the nurse call system for the JurongHealth Campus in Singapore.

The company will upgrade the Tacera Nurse Call platform that is installed in the 700-bed Ng Teng Fong General Hospital (NTFGH) and the 400-bed Jurong Community Hospital (JCH).

Austco was chosen as Tacera’s software is the only nurse call solution on the market that has voice over internet protocol (VoIP) to the patients’ bedside and provides a foundation for future products and services.

The Tacera solution will be integrated with JurongHealth’s Code Blue Platform. The combined technology will be able to deliver the fastest code blue rapid response of any hospital in Singapore.

NTFGH and JCH were the first hospitals in Singapore to be designed and built together from the ground up as an integrated healthcare development.

“We are aligned with JurongHealth’s mission of advancing healthcare by synergizing technology,” Austco CEO Clayton Astles said.

“At Austco, our focus is on providing innovative solutions, like our exceptional Tacera nurse call system, that delivers quality care and optimises the patient experience,” he added.

On market close, Austco is up 14.1 per cent and is trading at 10.5 cents per share.

AHC by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…